

China's Codex Genetics expands precision oncology portfolio with Cxbladder Genomic urine tests

11 August 2025 | News

Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring



Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, has announced an exclusive collaboration with New Zealand-based Pacific Edge, the developer of the Cxbladder suite of non-invasive genomic urine tests, to bring its advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong.

Under this partnership, Codex Genetics will offer access to Cxbladder's full range of clinically validated tests—including Cxbladder Detect, Cxbladder Monitor, and Cxbladder Triage—designed to support urologists and oncologists in the risk stratification and surveillance of urothelial bladder cancer. These precision urine-based tests integrate genomic biomarker analysis with clinical algorithms to deliver actionable insights earlier in the patient care pathway.

Importantly, following a February 2025 update, Cxbladder Triage is included in the Microhematuria Guideline issued by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). The amended Guideline incorporates language supporting the use of urine-based biomarkers to reduce reliance on cystoscopy and Cxbladder Triage is mentioned specifically, supported with "Grade A" evidence from a randomized controlled trial – the STRATA study.

Bladder cancer is the ninth most common cancer worldwide, with high recurrence contributing to its significant clinical and economic burden. Cxbladder has been used in over 100,000 patients globally and is supported by more than 25 peer-reviewed clinical studies demonstrating high sensitivity and negative predictive value. Its adoption can reduce the need for unnecessary invasive procedures and optimize clinical decision-making.